Table 5

Odds ratios for postmenopausal breast cancer by haplotypes in the vitamin D receptorgene under the log-additive model

Haplotypea
Haplotype frequencies (%)
OR (95% CI)



Cases (n = 1,408)
Controls (n = 2,612)
Crude modelb
Adjusted modelc

FTCG
0.178
0.183
1

1

FTCA
0.036
0.049
0.76
(0.51–1.15)
0.81
(0.53–1.23)
FTTG
0.124
0.116
1.12
(0.87–1.43)
1.09
(0.84–1.40)
FTTA
0.025
0.025
1.10
(0.69–1.77)
1.16
(0.71–1.88)
FtCG
0.117
0.113
1.07
(0.83–1.38)
1.06
(0.82–1.39)
FtCA
0.052
0.035
1.50
(1.07–2.12)
1.43
(1.00–2.05)
FtTG
0.076
0.079
0.98
(0.76–1.27)
1.04
(0.80–1.36)
FtTA
0.016
0.015
1.05
(0.59–1.87)
0.98
(0.54–1.79)
fTCG
0.109
0.117
0.97
(0.75–1.24)
0.97
(0.75–1.26)
fTCA
0.028
0.023
1.19
(0.72–1.96)
1.17
(0.70–1.95)
fTTG
0.080
0.083
0.98
(0.75–1.26)
1.04
(0.80–1.35)
fTTA
0.011
0.011
1.07
(0.48–2.37)
0.93
(0.41–2.09)
ftCG
0.048
0.041
1.19
(0.84–1.69)
1.19
(0.82–1.72)
ftCA
0.024
0.027
0.94
(0.57–1.55)
0.95
(0.56–1.64)
ftTG
0.065
0.072
0.94
(0.71–1.25)
0.94
(0.70–1.27)

aFokI, TaqI, VDR-5132, Cdx2 (with > 1% frequency in the study population). bUnconditional haplotype analysis adjusted for matching factor year of birth. cUnconditional haplotype analysis adjusted for year of birth, age at menopause, first-degree family history of breast cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of mammograms, use of hormone therapy, body mass index, education level and smoking status. CI, confidence interval; OR, odds ratio.

Abbas et al. Breast Cancer Research 2008 10:R31   doi:10.1186/bcr1994